Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of NVP-1805 vs Components in Healthy Male Volunteers
NCT04780386Phase 1Completed
- Sponsor
- NVP Healthcare Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NVP-1805 in cardiovascular diseases (CVD) (2 arms), sponsored by NVP Healthcare Co., Ltd. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and Maximum Plasma Concentration. Started Aug 2020; status: completed.
02
Drugs
NVP-1805
03
Conditions
cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT04780386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780386.